Dec 4, 2014
Photoreceptor cells in the eye capture light, making vision possible. In retinal diseases such as retinitis pigmentosa and dry age-related macular degeneration, photoreceptors die, causing vision loss. Why do photoreceptors die? This question motivates many FBC-funded scientists, who are looking for ways to protect these cells and prevent them from dying.
FBC-funded scientist Dr. Phillipe Monnier is especially interested in cells that are dying through a process called apoptosis, also known as programmed cell death. Apoptosis occurs when photoreceptors are “programmed” to die from signals that are being sent from other cells. What if there was a way to block or modify these signals? Dr. Monnier’s research is focused on developing strategies to block death signals from reaching photoreceptor cells, thereby preventing their degeneration.
His strategies are centered on a particular receptor, Neogenin, which is located on the outer membrane of photoreceptor cells. Dr. Monnier’s latest breakthrough, which appears in the prestigious journal Cell Reports, shows that blocking Neogenin significantly enhances cell survival. This is fantastic news for those suffering from retinal degeneration because there is growing evidence that Neogenin is a key player in multiple cellular events occurring in eye diseases. Dr. Monnier has been involved in research in this area from the earliest basic science discoveries, and with regard to a range of conditions (glaucoma, spinal injury, stroke). We are proud to be funding his efforts to apply these findings towards therapies for retinal degenerative disease.
The eye is both an extension of and window into the brain, which makes it an ideal experimental environment for evaluating neuroprotective therapies. Indeed, these latest results suggest that focusing on Neogenin has the potential to generate a unified strategy to promote brain cell survival.
About the Study:
The paper appeared online August 21, 2014 in Cell Reports with the title: “Modifying Lipid Rafts Promotes Regeneration and Functional Recovery.” The authors include Nardos Tassew, Andrea Mothe, Alireza Shabanzadeh, Paromita Banerjee, Paulo Koeberle, Rod Bremner, Charles Tator, and Philippe Monnier. Both Dr.’s Monnier and Bremner are funded by Fighting Blindness Canada and are affiliated with the Toronto Western Research Institute and the Department of Ophthalmology at the University of Toronto.
Latest FBC News View All
A Message from the President and CEO For 45 years, the Foundation Fighting Blindness has raised and directed critical funding into sight-saving research for blinding eye diseases. From our earliest days as…Read More
In light of a recent article published by the Globe and Mail regarding the potential correlation between Avastin injections and increased glaucoma rates specifically in British Columbia, Fighting Blindness Canada is republishing…Read More
We are letting our community know about a patient experience study being conducted by Medicys Ltd., a medical research company that is looking for people with a confirmed diagnosis of Usher syndrome…Read More
On May 28, 2019, Dr. Chad Andrews, Senior Manager of Research and Education at Fighting Blindness Canada, will be taking part in Dispelling Myths Surrounding the Vision of Older People, an interdisciplinary…Read More
Join the Fight!
Learn how your support is helping to bring a future without blindness into focus! Be the first to learn about the latest breakthroughs in vision research and events in your community by subscribing to our eNews.